Inhibition of Akt signaling suppressed tumor progression in glioblastoma stem cells, indicating potential therapy.
In summary, MK-2206 outperformed iCRT3 efficacy in vitro, and suppressed GBM progression, in vivo. These findings suggest that Akt inhibition via MK-2206 may offer a promising therapeutic strategy for treating GBM, characterized by dysregulation of PI3K/Akt or Wnt/β-catenin pathways.
No takes yet. Share an insight, caveat, or question.
Sarkar et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: